NCT04562389Phase 3Active not recruiting

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

Study sponsor: Karyopharm Therapeutics Inc · KPTI

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-02-20Actual

Enrollment · participants353Actual

Source updated2026-04-09Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-09 · 2 fields changed

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Mar 2026~~

+ After

20 Feb 2026

Check registry source

Posted 2025-10-03 · 4 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~350 participants (planned)~~

+ After

353 participants (actual)

Primary completion date changed

− Before

~~Sep 2025~~

+ After

Mar 2026

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Myelofibrosis

Treatments or interventions studied

SelinexorDrugAlso known as KPT-330
SelinexorDrugAlso known as KPT-330
RuxolitinibDrug

Primary outcomes · main study measures

Read the study measures

measure: Phase 3: Proportion of Participants with Spleen Volume Reduction (SVR) of Greater than or Equal to (>=) 35 Percent (%) (SVR35) at Week 24 Measured by the Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan; timeFrame: At Week 24; measure: Phase 3: Absolute mean change in TSS (Abs-TSS) from baseline to Week 24 as measured by the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0; timeFrame: At Week 24; measure: Phase 1: Maximum Tolerated Dose (MTD); timeFrame: Approximately within the first cycle (28 days) of therapy; measure: Phase 1: Recommended Phase 2 Dose (RP2D); timeFrame: Approximately within the first cycle (28 days) of therapy; measure: Phase 1: Number of Participants With Adverse Events (AEs) by Occurrence, Nature, and Severity; timeFrame: From start of drug administration up to 30 days after last dose of study treatment (approximately 48 months)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history